Literature DB >> 10478578

A multidimensional assessment of multiple sclerosis: relationships between disability domains.

L Provinciali1, M G Ceravolo, M Bartolini, F Logullo, M Danni.   

Abstract

OBJECTIVE: To test the feasibility of a multidimensional assessment based on both task-related and self-evaluation questionnaire scores in patients with multiple sclerosis (MS); ii) to correlate the results from selective measures with the severity of illness in terms of the Expanded Disability Status Scale (EDSS) score; iii) to assess the relationships between different domains of MS-related disability and handicap. PATIENTS AND METHODS: Eighty-three MS patients (M/F 31/52; age 43.26 +/- 10.9 years, range 21-72) underwent a standard clinical evaluation of motor abilities (by means of the Rivermead Mobility index, Timed Walking Test, Nine Hole Peg test and Hauser Ambulation Index) and cognitive performances (using Digit Symbol, Buschke-Fuld selective remind test, "FAS"-Word Fluency, Wisconsin Card Sorting test and Block design test). The Beck Depression inventory, MS Specific Fatigue Scale, Functional Assessment of MS and London Handicap Scale were applied to evaluate mood, fatigue, quality of life and handicap, respectively. Minimal Record of Disability measures - MRD (i.e. EDSS, Inability Status Scale and Environmental Status Scale) were also applied to test the criterion validity of the selected disability and handicap scales. The Kruskal-Wallis H-test for independent samples tested differences between subgroups with an increasing EDSS score (<3.5, 3.5-6.0, >6.0). The covariance and redundancy of measures included in the multidimensional assessment were evaluated through Factor Analysis. The Multiple Regression Analysis was used to detect the relative impact of either motor or cognitive disabilities and depression on handicap and quality of life.
RESULTS: The multimodal assessment took 70 min on average to be performed, being well accepted by patients. Motor abilities worsened as the EDSS score rose, unlike cognitive performances which proved to be similarly impaired at different severity levels. Measures of fatigue and depression were not related to EDSS values. The chosen measures were assigned by Factor Analysis to 4 domains corresponding to motor performance, executive performance, cognitive abilities and quality of life, respectively. Regression analysis showed how handicap and depression independently affect quality of life. While the handicap score is mostly influenced by motor ability, as measured by the Rivermead Mobility Index, the depression score grows independently of any physical or cognitive disability and seems to be related to fatigue self-assessment scores.
CONCLUSIONS: A multidimensional approach to MS patient assessment allows a more detailed and sensitive evaluation of their disability profile and perceived difficulties, leading to a care programme tailored to the patient's needs.

Entities:  

Mesh:

Year:  1999        PMID: 10478578     DOI: 10.1111/j.1600-0404.1999.tb00731.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

1.  Changes in gait and fatigue from morning to afternoon in people with multiple sclerosis.

Authors:  M E Morris; C Cantwell; L Vowels; K Dodd
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

2.  Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients.

Authors:  Stacey Hart; Irina Fonareva; Natalia Merluzzi; David C Mohr
Journal:  Qual Life Res       Date:  2005-04       Impact factor: 4.147

Review 3.  Fatigue in multiple sclerosis.

Authors:  L B Krupp; C Christodoulou
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

4.  Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers.

Authors:  Marta Bassi; Monica Falautano; Sabina Cilia; Benedetta Goretti; Monica Grobberio; Marianna Pattini; Erika Pietrolongo; Rosa Gemma Viterbo; Maria Pia Amato; Miriam Benin; Alessandra Lugaresi; Eleonora Minacapelli; Enrico Montanari; Francesco Patti; Maria Trojano; Antonella Delle Fave
Journal:  J Clin Psychol Med Settings       Date:  2016-03

Review 5.  Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression.

Authors:  Michele L Pucak; Katherine A L Carroll; Douglas A Kerr; Adam I Kaplin
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

6.  The impact of disability, fatigue and sleep quality on the quality of life in multiple sclerosis.

Authors:  Haleh Ghaem; Afshin Borhani Haghighi
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

7.  Quality of life in multiple sclerosis: translation in French Canadian of the MSQoL-54.

Authors:  Catherine Acquadro; Louise Lafortune; Isabelle Mear
Journal:  Health Qual Life Outcomes       Date:  2003-11-24       Impact factor: 3.186

8.  Increased plasma homocysteine levels in patients with multiple sclerosis and depression.

Authors:  Nikolaos Triantafyllou; Maria-Eleftheria Evangelopoulos; Vasilios K Kimiskidis; Evangelia Kararizou; Fotini Boufidou; Konstantinos N Fountoulakis; Melina Siamouli; Chrysoula Nikolaou; Constantinos Sfagos; Nikolaos Vlaikidis; Dimitrios Vassilopoulos
Journal:  Ann Gen Psychiatry       Date:  2008-09-09       Impact factor: 3.455

9.  Prevalence and risk factors for depression in women with multiple sclerosis: a study from Iran.

Authors:  Khadijeh Mohammadi; Parvin Rahnama; Ali Montazeri
Journal:  Ann Gen Psychiatry       Date:  2015-09-22       Impact factor: 3.455

Review 10.  Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation.

Authors:  Moussa A Chalah; Naji Riachi; Rechdi Ahdab; Alain Créange; Jean-Pascal Lefaucheur; Samar S Ayache
Journal:  Front Cell Neurosci       Date:  2015-11-30       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.